Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ) operates in various business sectors.
Sprint Bioscience AB (publ) (5JA1) - Total Assets
Latest total assets as of June 2024: €48.30 Million EUR
Based on the latest financial reports, Sprint Bioscience AB (publ) (5JA1) holds total assets worth €48.30 Million EUR as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sprint Bioscience AB (publ) - Total Assets Trend (2018–2023)
This chart illustrates how Sprint Bioscience AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sprint Bioscience AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2023)
Sprint Bioscience AB (publ)'s total assets of €48.30 Million consist of 92.8% current assets and 7.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 80.1% |
| Accounts Receivable | €802.00K | 1.3% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how Sprint Bioscience AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sprint Bioscience AB (publ)'s current assets represent 92.8% of total assets in 2023, an increase from 30.9% in 2018.
- Cash Position: Cash and equivalents constituted 80.1% of total assets in 2023, up from 24.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 65.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
Sprint Bioscience AB (publ) Competitors by Total Assets
Key competitors of Sprint Bioscience AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Sprint Bioscience AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Sprint Bioscience AB (publ) generates 0.81x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Sprint Bioscience AB (publ) is currently not profitable relative to its asset base.
Sprint Bioscience AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.47 | 1.10 | 9.29 |
| Quick Ratio | 1.47 | 1.10 | 9.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €14.04 Million | € 1.95 Million | € 82.12 Million |
Sprint Bioscience AB (publ) - Advanced Valuation Insights
This section examines the relationship between Sprint Bioscience AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 66.7% |
| Total Assets | €62.38 Million |
| Market Capitalization | $1.77K USD |
Valuation Analysis
Below Book Valuation: The market values Sprint Bioscience AB (publ)'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sprint Bioscience AB (publ)'s assets grew by 66.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sprint Bioscience AB (publ) (2018–2023)
The table below shows the annual total assets of Sprint Bioscience AB (publ) from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €62.38 Million | +66.69% |
| 2022-12-31 | €37.42 Million | -52.71% |
| 2021-12-31 | €79.14 Million | +136.94% |
| 2020-12-31 | €33.40 Million | +73.56% |
| 2019-12-31 | €19.24 Million | -67.54% |
| 2018-12-31 | €59.29 Million | -- |